The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar M2 – Risk analysis of the drug development process – focus on the patient
Affiliation
Heymans Institute of Pharmacology and Drug Research Unit Ghent (D.R.U.G.), Ghent University
Country
Belgium
1. Current Status, Position
Prof Dr Van Bortel is Professor clinical pharmacology and pharmacotherapy and Head of D.R.U.G., the University Hospital Unit for early phase clinical drug development.
2. Education
As medical doctor Luc Van Bortel specialized in internal medicine and clinical pharmacology. He obtained a PhD degree at Maastricht University where he was associate professor clinical pharmacology. From 2000 Luc Van Bortel is chairing the clinical pharmacology Unit at Ghent university. He is a certified trainer in clinical pharmacology.
3. Research Area
He has 28 years experience in early phase clinical drug development. Besides the early phase clinical drug development Luc Van Bortel’s research is situated in the cardiovascular domain, and in arterial research in particular. He is currently president of the ARTERY Society.
Conflict of interest: None